Anorexia News and Research

RSS

Millennium submits two VELCADE sNDAs to FDA

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that it has submitted two supplemental new drug applications (sNDAs) for VELCADE® (bortezomib) for Injection to the U.S. Food and Drug Administration. The first application seeks to add a subcutaneous route of administration for VELCADE. The second application is for the use of VELCADE in combination with rituximab in patients with relapsed follicular non-Hodgkin lymphoma (NHL).

26 Apr 2011

Pfizer to support immatics' IMA901 Phase III trial in advanced renal cell carcinoma

immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that Pfizer has agreed to support its pivotal Phase III trial with IMA901, its therapeutic cancer vaccine for advanced renal cell carcinoma.

11 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

Eating disorders - hitting early and hard

Children as young as seven have been admitted to hospitals for eating disorders. A peak support group has reported a doubling of calls about children under the age of 12 in the past decade. Being hit so early with these disorders also means malnutrition leading to retarded growth, osteoporosis, infertility and changes in brain structure say experts.

30 Mar 2011

Eating disorders tough to conquer

Young people and adolescents have been repeatedly warned regarding eating disorders. Lisa Harmon Mollicone, coordinator of the Manalapan-Englishtown Community Alliance for the Prevention of Alcohol and Drug Abuse, addressed the topic of eating disorders at a full house during the Dec. 14 meeting of the alliance, held at the Manalapan Senior Center.

29 Mar 2011

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.

9 Mar 2011

Prevalence of eating disorders higher than previously thought

A new study shows that many American adolescents suffer from an eating disorder and struggle with related psychiatric disorders, including suicidal tendencies. The researchers write, “The prevalence of these disorders is higher than previously expected in this age range, and the patterns of [co-existing illnesses], role impairment and suicidality indicate that eating disorders represent a major public health concern.” Led by Sonja A. Swanson, of the National Institute of Mental Health, the research team reported the findings online March 7 in the Archives of General Psychiatry.

7 Mar 2011

Vertex announces positive interim results from telaprevir Phase 2 study in patients with HCV, HIV

Vertex Pharmaceuticals Incorporated announced today interim results from an ongoing, two-part, Phase 2 study evaluating telaprevir in combination with pegylated-interferon and ribavirin compared to pegylated-interferon and ribavirin alone in people who are infected with both genotype 1 hepatitis C virus and human immunodeficiency virus, also known as HCV-HIV co-infection.

3 Mar 2011

Onyx, Bayer initiate patient enrollment in Nexavar Phase 3 trial for breast cancer treatment

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced the companies have begun enrolling patients in a Phase 3 randomized, double-blind, placebo-controlled trial evaluating Nexavar tablets in combination with the oral chemotherapeutic agent, capecitabine, versus placebo plus capecitabine for the treatment of patients with advanced breast cancer.

24 Feb 2011

New study: Cannabis ingredient can improve appetites and sense of taste in cancer patients

The active ingredient in cannabis can improve the appetites and sense of taste in cancer patients, according to a new study published online in the cancer journal, Annals of Oncology today.

23 Feb 2011

Online Negative Enabling Support Group embraces anorexia as a choice

It can be a helpless and heartbreaking situation for families as they try to confront a family member with an eating disorder. What they may not know is that there's a society on the Internet that is dedicated to thwarting any recovery from this dangerous and possibly fatal behavior.

23 Feb 2011

Study: Women with anorexia draw themselves with prominently different characteristics

Women suffering from anorexia or bulimia draw themselves with prominently different characteristics than women who do not have eating disorders and who are considered of normal weight. This has been revealed in a new joint study from the University of Haifa, Soroka University Medical Center and Achva Academic College, Israel, published in The Arts in Psychotherapy.

14 Feb 2011

Urocortin system plays central role in regulating stress responses

Post-traumatic stress disorder can affect soldiers after combat or ordinary people who have undergone harrowing experiences. Of course, feelings of anxiety are normal and even desirable - they are part of what helps us survive in a world of real threats. But no less crucial is the return to normal - the slowing of the heartbeat and relaxation of tension - after the threat has passed.

9 Feb 2011

Study reveals Facebook users may face risk of developing eating disorders

The same has been found with regard to exposure to music and fashion on the Internet, and to harmful programs on TV. The study also reveals that the risk of developing eating disorders in adolescent girls is moderated when there is more parental supervision over viewing habits.

8 Feb 2011

Phase II results of VELCADE in patients with aggressive lymphoma published in Journal of Clinical Oncology

Millennium: The Takeda Oncology Company today announced that Phase II results of a clinical trial examining VELCADE (bortezomib) in patients with previously untreated aggressive lymphoma were published in the Journal of Clinical Oncology.

5 Feb 2011

GSA commends '2010 Dietary Guidelines for Americans'

The Gerontological Society of America (GSA) - the nation's largest interdisciplinary organization devoted to the field of aging - commends the federal government's recent release of the "2010 Dietary Guidelines for Americans" and particularly applauds its inclusion of specific advice for older adults.

4 Feb 2011

Baxter launches OLIMEL emulsion for parenteral nutrition

Baxter International today announced the launch of OLIMEL emulsion for infusion in Canada at the American Society of Parenteral and Enteral Nutrition's Clinical Nutrition Week.

From Baxter International Inc. 31 Jan 2011

Way of experiencing internal state of body influences perception of body from the outside

A new study, led by Dr Manos Tsakiris from Royal Holloway, University of London, suggests that the way we experience the internal state of our body may also influence how we perceive our body from the outside, as for example in the mirror. The research appears today (5 January) in the Proceedings of the Royal Society B.

5 Jan 2011

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

Celgene International Sàrl announced regulatory submissions for its blood cancer therapies REVLIMID (lenalidomide) and ISTODAX (romidepsin).